La Jolla faces quiet end following stock collapse
This article was originally published in Scrip
Executive Summary
La Jolla Pharmaceuticals will consider ending operations after the trial suspension of its only clinical candidate left its share price in tatters. The firm's share price tumbled by 92% to $0.20 earlier this month after a study of its lupus candidate Riquent (abetimus sodium) failed to show a benefit and was subsequently halted.